Geode Capital Management
CYCN icon

Geode Capital Management’s Cyclerion Therapeutics CYCN Stock Holding History

Geode Capital Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$130K Buy
84,550
+41,248
+95% +$58.7K ﹤0.01% 4065
2025
Q4 		$55K Buy
43,302
+6,144
+17% +$11K ﹤0.01% 4218
2025
Q3 		$85.5K Buy
37,158
+4,423
+14% +$12K ﹤0.01% 4169
2025
Q2 		$95.3K Buy
32,735
+1,132
+4% +$3.38K ﹤0.01% 4071
2025
Q1 		$78.1K Sell
31,603
-217
-0.7% -$646 ﹤0.01% 4099
2024
Q4 		$102K Sell
31,820
-2,088
-6% -$5.81K ﹤0.01% 4091
2024
Q3 		$87.5K Sell
33,908
-70
-0.2% -$206 ﹤0.01% 4144
2024
Q2 		$77.5K Buy
33,978
+1,896
+6% +$5.39K ﹤0.01% 4196
2024
Q1 		$103K Buy
32,082
+823
+3% +$2.63K ﹤0.01% 4153
2023
Q4 		$105K Buy
31,259
+510
+2% +$1.47K ﹤0.01% 4177
2023
Q3 		$105K Buy
30,749
+1,027
+3% +$3.7K ﹤0.01% 4235
2023
Q2 		$122K Buy
29,722
+110
+0.4% +$570 ﹤0.01% 4254
2023
Q1 		$257K Buy
29,612
+275
+0.9% +$3.47K ﹤0.01% 3922
2022
Q4 		$385K Buy
29,337
+146
+0.5% +$1.73K ﹤0.01% 3795
2022
Q3 		$502K Buy
29,191
+506
+2% +$8.7K ﹤0.01% 3725
2022
Q2 		$314K Sell
28,685
-484
-2% -$6.93K ﹤0.01% 4007
2022
Q1 		$647K Buy
29,169
+877
+3% +$21.1K ﹤0.01% 3816
2021
Q4 		$973K Buy
28,292
+3,759
+15% +$178K ﹤0.01% 3738
2021
Q3 		$1.51M Buy
24,533
+5,292
+28% +$346K ﹤0.01% 3485
2021
Q2 		$1.5M Sell
19,241
-5,107
-21% -$320K ﹤0.01% 3397
2021
Q1 		$1.36M Buy
24,348
+2,655
+12% +$199K ﹤0.01% 3430
2020
Q4 		$1.33M Buy
21,693
+4,044
+23% +$276K ﹤0.01% 3273
2020
Q3 		$2.15M Buy
17,649
+1,841
+12% +$211K ﹤0.01% 2843
2020
Q2 		$1.87M Sell
15,808
-342
-2% -$28.6K ﹤0.01% 2882
2020
Q1 		$855K Buy
16,150
+1,131
+8% +$80.7K ﹤0.01% 3077
2019
Q4 		$817K Buy
15,019
+2,725
+22% +$254K ﹤0.01% 3346
2019
Q3 		$2.98M Buy
12,294
+222
+2% +$48K ﹤0.01% 2695
2019
Q2 		$2.76M Buy
+12,072
New +$3.42M ﹤0.01% 2744

Other funds holding CYCN

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Geode Capital Management's CYCN Position: Q1 2026 in Review

Geode Capital Management increased its Cyclerion Therapeutics (CYCN) stake by 95% in Q1 2026, buying an estimated $58.7K and bringing the position to 84,550 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #4065.

Geode Capital Management first reported a position in CYCN in Q2 2019 and has held it in 28 quarters since. The position peaked at $2.98M in Q3 2019. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

  • Geode Capital Management held 84,550 shares of Cyclerion Therapeutics worth $130K as of Q1 2026.
  • Geode Capital Management bought 41,248 Cyclerion Therapeutics shares in Q1 2026, an estimated $58.7K.
  • Cyclerion Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4065 holding.
  • Geode Capital Management first reported a position in Cyclerion Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Geode Capital Management's Cyclerion Therapeutics position peaked at $2.98M in Q3 2019.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.